Clinical Trial Update: Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) [Phase 2]

View source ↗

Summary

Phase IIa proof-of-concept study CAPTURE 1 evaluating the fixed-dose combination M5717-Pyronaridine in adults and adolescents with acute uncomplicated Plasmodiu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• M5717-Pyronaridine (M5717 + Pyronaridine)

Snippet

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Acute Malaria | Phase 2 | Status: COMPLETED | Results posted: 2025-08-27